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Abstract
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is the most frequent inborn error of metabolism and
accounts for 90–95% of CAH cases. In the present work, we analyzed the functional consequence of four novel previously
reported point CYP21A2 mutations -p.R132C, p.R149C, p.M283V, p.E431K- found in Argentinean 21-hydroxylase deficient
patients. In addition, we report an acceptor splice site novel point mutation, c.652-2A.G, found in a classical patient in
compound heterozygosity with the rare p.R483Q mutation. We performed bioinformatic and functional assays to evaluate
the biological implication of the novel mutation. Our analyses revealed that the residual enzymatic activity of the isolated
mutants coding for CYP21A2 aminoacidic substitutions was reduced to a lesser than 50% of the wild type with both
progesterone and 17-OH progesterone as substrates. Accordingly, all the variants would predict mild non-classical alleles. In
one non-classical patient, the p.E431K mutation was found in cis with the p.D322G one. The highest decrease in enzyme
activity was obtained when both mutations were assayed in the same construction, with a residual activity most likely
related to the simple virilizing form of the disease. For the c.652-2A.G mutation, bioinformatic tools predicted the putative
use of two different cryptic splicing sites. Nevertheless, functional analyses revealed the use of only one cryptic splice
acceptor site located within exon 6, leading to the appearance of an mRNA with a 16 nt deletion. A severe allele is strongly
suggested due to the presence of a premature stop codon in the protein only 12 nt downstream.
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Introduction
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase
deficiency (OMIM 201910) accounts for 90–95% of CAH cases
[1,2]. This autosomal recessive disorder, which is the most
frequent inborn error of metabolism, has a broad spectrum of
clinical forms, ranging from severe or classical (CCAH) to the mild
late onset or non-classical one (NCCAH) [1]. The classical form
includes salt-wasting (SW) and simple virilizing (SV) variants,
depending on the degree of aldosterone deficiency. Girls with
classical CAH are typically born with ambiguous genitalia.
Patients with NCCAH exhibit clinical manifestations of hyperan-
drogenism.
Neonatal screening programs performed since 1977 have shown
an overall incidence of 1:15000 live births for the classical form [3–
6]. On the other hand, NCCAH is estimated to be more common
than CCAH, with a prevalence of 1:1000 in the white population,
and more frequent in certain ethnic groups such as Jews of Eastern
Europe, Hispanics and Yugoslavs [7].
The affected enzyme, CYP21A2, is encoded by the CYP21A2
gene. This gene is located in 6p21.3 adjacent to a pseudogene,
CYP21A1P, with which it shares 98% of nucleotide sequence
identity. Due to the high degree of identity between CYP21A2 gene
and its pseudogene, most of the disease-causing mutations are
likely the consequence of non-homologous recombination or gene
conversion events [8,9]. Even though most patients carry
CYP21A1P-derived mutations, an increasing number of naturally
occurring mutations have been found in disease-causing alleles in
the last years (see: http://www.hgmd.cf.ac.uk for details). Muta-
tions in the CYP21A2 gene cause varying degrees of 21-
hydroxylase activity loss [10]. In vitro studies have revealed that
usually mutations leading to a complete inactivation of 21-
hydroxylase activity are associated with the SW phenotype. Those
that reduce enzyme activity close to 2% cause the SV phenotype,
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e92181
.
while those with a remaining enzymatic activity in the range of
10% to 70% result in the mild NCCAH phenotype.
Recently, efforts have been made towards predicting activities of
mutant proteins and homology modeling has emerged as a useful
tool to evaluate, through structure-based methods, protein activity
or stability impairment. Although the use of approximate models
allows making some predictions with certain accuracy [11–13],
in vitro studies should be conducted to further analyze the putative
biological implication of the mutant alleles. Moreover, the severity
of the impairment of enzymatic activity of two mild mutations on
the same allele could be difficult to predict in the absence of
functional studies, studies being essential for genetic counselling as
this allele could represent a severe one.
In this paper, we analyzed the functional consequence of four
previously reported novel point CYP21A2 mutations leading to
aminoacidic substitutions, p.R132C, p.R149C, p.M283V,
p.E431K, found in Argentine patients [12]. For these mutations,
in silico molecular modeling analyses have revealed changes in the
stability and/or surface charge of the protein that could be related
to the clinical manifestations found in the patients [12].
In addition, we report a novel point mutation, c.652-2A.G, in
the intron 5 acceptor splicing site found in a SV patient from our
cohort in compound heterozygosity with the rare p.R483Q
mutation. Its pathogenic functional implication was also analyzed
by means of bioinformatic predictions and functional assays.
Materials and Methods
All clinical investigations were conducted according to the
principles expressed in the Declaration of Helsinki and written
informed consent was obtained from the patient. The study was
approved by the Ethic Committee of the Instituto de Biologı´a y
Medicina Experimental, Buenos Aires, Argentina.
Patients
Clinical symptoms of the patients in whom the four aminoacidic
mutations were found have been described previously [12].
Physical and endocrine evaluation of the patient in whom the
novel mutation in the intron 5 acceptor splicing site was found,
was conducted at the Division Endocrinologı´a of the Hospital
Durand, Buenos Aires, Argentina. Clinical characteristics and
hormonal profile of this SV patient are presented in Text S1.
Materials
Primers were from Sigma-Aldrich (St. Louis, MA). Fugene HD
Transfection, b-galactosidase pSV-Gal vector, lysis buffer and b-
Galactosidase Enzyme Assay System were obtained in Promega
(Madison, WI). PureLink, Quick Plasmid Miniprep Kit, DMEM
medium High Glucose and Pyruvate, Lipofectamine, and MMLV-
RT reverse transcriptase were purchased in Invitrogen (Carlsbad,
CA). Wild-type plasmid pCMV4-CYP21A2 was kindly provided
by Dr. A. Wedell (Karolinska Institute, Sweden) and antihuman
CYP21A2 rabbit polyclonal antiserum was kindly provided by Dr.
W. L. Miller (University of San Francisco, San Francisco, CA).
QuikChange multi-site-directed mutagenesis kit was obtained in
Stratagene (La Jolla, CA). Radioactive substrates were from
Perkin-Elmer (Boston, MA). Rabbit anti b-actin antibody was
purchased in Santa Cruz Biotechnology (Santa Cruz, CA).
QIAquick Gel Extraction Kit was from Qiagen (Hilden, Germany)
and Tris Reagent was from Molecular Research Center, Inc.
(Cincinnati, OH). Silica gel plates 60GF 254 on aluminum were
purchased from Merck (Darmstadt, Germany). Scintillation
counting was carried out with Wallac 1409 DSA equipment with
OptiPhase-Hi safe 3 as scintillation cocktail (Wallac Co, Turku,
Finland).
DNA Analyses
Nucleotide numbering was performed following the guidelines
of the Human Genome Variation Society [14], using M13936.1
[15] as the genomic CYP21A2 reference sequence and
NM_000500.7 NCBI Reference Sequence for mRNA. All new
data has been deposited in GeneBank database.
Screening of the 10 most frequent mutations in the CYP21A2
gene in DNA sample from the CCAH patient was performed as
previously described [16,17]. Since none of these points of
mutations were found, DNA was further analyzed by direct
sequencing [12]. Parents were not available, thus the presence of
mutations in trans was assumed. In addition, DNA samples of 50
randomly selected subjects from the general population were
screened for the novel mutation. Briefly, a CYP21A2 specific
fragment from exon 1 to exon 6 was amplified with primers
already described [18,19]. Screening of the g.1329A.G (c.652-
2A.G, Genbank KF051996) mutation was performed in a second
round of PCR by amplification of a 696-bp fragment spanning
exon 3 to 6 [12], followed by a BtgI restriction enzyme assay and a
2% Ethidium Bromide-stained agarose gel electrophoresis. Frag-
ments from wild type allele were of 84 and 612 bp, while the
mutant allele rendered 75, 84 and 537 bp fragments.
Bioinformatic Analysis
In silico analysis was performed to assess the disrupted effect of
c.652-2A.G mutation and the presence of putative cryptic
acceptor sites. This search was performed using The Human
Splicing Finder tool (HSF, http://www.umd.be/HSF/) [20]. A
fragment of 206 pb ranging from nt 1221 in the 39 end of exon 5
to nt 1425 in the exon 6 was analyzed. For the examination of
putative cryptic sites, a threshold of 80% in the consensus value
(CV) was considered, as it represents a value for strong splicing
sites. Likewise, a reduction in the CV (DCV) of at least 10% for a
mutation is likely to have a significant impact on splicing and
should be further investigated [20].
In vitro Expression and Assay of 21-hydroxylase Activity
In vitro studies were carried out for the aminoacidic mutations as
described by Krone et al. [21] with slightly modifications. Since the
p.E431K mutation was found in cis with another described point
mutation (p.D322G) [22], all the variants were tested in isolation
and the double mutant was also analyzed. The p.I172N with
about 2% residual activity and responsible for SV form [23] was
used as a low-activity positive control. Mutagenesis of the wild-
type (WT) pCMV4-CYP21A2 plasmid was performed with the
QuikChange multi-site-directed mutagenesis kit according to the
manufacturer’s instructions. At least two different colonies for each
mutation were collected, and the plasmids verified by sequencing
the whole insert. The tested plasmids were: WT- pCMV4-
CYP21A2 for reference, pCMV4 without CYP21A2cDNA as
negative control, and mutated pCMV4-CYP21A2.
Approximately 1.66105 COS-7 cells (ATCC CRL-1651) were
transiently transfected by Fugene HD Transfection with 1 mg each
of pCMV4-CYP21A2 construct and b-galactosidase pSV-Gal
vector in 6 well plate and incubated in DMEM-F12 medium
supplemented with 10% fetal bovine serum (FBS) for 48 h. COS-7
line was used up to 10 passages. The activity of 21-hydroxylase in
intact COS-7 cells was determined after transfection by measuring
the conversion of [3H]progesterone and [3H]17-hydroxyproges-
terone (17-OHP) into [3H]deoxycorticosterone and [3H]11-
deoxycortisol, respectively. Cells were incubated with 0.5 mCi of
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each of the radioactive substrates and 2.0 mM unlabeled steroids
with or without 5 mM NADPH, 1h at 37uC. Media were collected
and steroids analyzed by thin layer chromatography (TLC) as
previously described [24]. Substrate conversion rates for mutant
CYP21A2 were compared with those of WT enzyme. Cells were
washed with PBS and 400 ml lysis buffer was added. Plates were
incubated during 15 min on ice-water bath and subsequently
homogenized in the same buffer. Homogenates were centrifuged
and the supernatant transferred to clean tubes. Proteins in the
lysate were quantified by Bradford assay [25], and b-galactosidase
activity was measured by b-Galactosidase Enzyme Assay System
according to manufacturer’s instructions. The activity of mock
transfection was deducted in each experiment. Enzyme activities
of the mutants were expressed as percentage of WT CYP21A2-
activity that was defined as 100%. Each experiment was
performed two to four times and the ratio of b-galactosidase
activity to total protein content was measured in each experiment
to verify the reproducibility of transfection.
Expression of the WT and mutant proteins was studied by
Western blotting. A total amount of 23 mg of protein was
electrophoresed in 10% SDS-PAGE gel. After transference,
membranes were incubated for 10 min in PBS-0.1% Tween-20
(PBS-T) and 3% hydrogen peroxide and blocked for 1 hr at room
temperature in PBS-T containing low-fat powdered milk (5%).
Incubations with primary antibodies were performed over night at
4uC with 1/30000 antihuman CYP21A2 rabbit polyclonal
antiserum [26] or 1/800 mouse anti b-actin antibody. Secondary
antibodies were anti-mouse and anti-rabbit conjugated to perox-
idase. Immunopositive bands were detected using 1.25 mM
luminol, 0.198 mM cumaric acid and 0.038% v/v hydrogen
peroxide in 100 mM Tris-HCl buffer. Densitometric analysis of
the corresponding bands was performed with the ImageGauge
software (Fuji photo film CO., LTD, Altura Software Inc). At least
two different extracts were analyzed for each mutant and each of
them was processed twice. Protein levels of the different CYP21A2
constructs were expressed as the ratio between CYP21A2 and b-
actin, considering b-galactosidase activity as the control for
transfection efficiency. For quantification, the background expres-
sion of the mock construct was deducted.
Minigene Construction, Transfection and mRNA Analysis
A minigene with a fragment spanning from exon 4 to exon 7
was constructed. After the first amplification to select CYP21A2
gene [16], a nested-PCR was performed to construct the minigene
with the following primers: exon 4 sense-BstEII 59-
GCGGGTGACCCATCATCTGTTACCTCACCTTC-39 and exon 7 anti-
sense-BsteII 59-GCCGGTCACCGTTTGCTGTGGTCTCAGTG-39. PCR
product was digested with BstEII and ligated into a BstEII digested
pSVEDEDBXho vector [27]. Clones were sequenced to verify
their identity. Recombinant plasmids were purified by PureLink,
Quick Plasmid Miniprep Kit, and transfected in HEK-293 (ATCC
CRL-1573), HeLa (ATCC CCL-2) and Y-1 cells (ATCC CCL-
79). For HEK-293 and HeLa cells, approximately 26105 cells
were plated in a 6 well plate containing DMEM medium high
glucose with or without pyruvate, respectively, and supplemented
with 10% FBS and. After 24 hours, HEK-293 and HeLa cell
cultures were transfected with 2 mg of total DNA (100 ng of
minigene and the rest pBlueScript used as carrier DNA) using
Lipofectamine 6 ml/well. For Y-1 cells, approximately 56104 cells
were plated in a 24 well plate containing HAM-F10 medium
supplemented with 2.5% FBS, 12.5% horse serum. After 24 hours
Y-1 cells cultures were transfected with Fugene HD (2 ml/mg of
DNA). All cell lines were used up to 10 passages.
Cells were collected 48 hours after transfection and total RNA
was isolated by using Tris Reagent. First-strand synthesis was
performed using MMLV-RT reverse transcriptase. The cDNA
was amplified by PCR using the following primers spanning the
pSVEDEDBXho vector: sense 59ACTGCCTGCTGGTGACC-
CATC39 and antisense 59CGGCCAGGGTCACCGTTTG39 in
the presence of 0.5 mCi of helloa32-P]dCTP, resolved in a 6%
acrylamide-bisacrylamide (29:1) gel and revealed by autoradiog-
raphy. An aliquot of a non-radioactive PCR was further analyzed
by direct sequencing.
Results
Novel Mutation
Five novel disease-causing mutations were detected in patients
from our cohort. Four out of five were associated with NCCAH
patients: p.R132C, p.R149C, p.M283V and p.E431K, and were
previously described [12]. One of the mutations, g.1329A.G,
now named c.652-2A.G, is herein described for the first time
(Figure 1A) and was found in a SV patient. The g.1329A.G
mutation was not detected in 100 chromosomes of randomly
selected individuals of the general population (1B).
The intronic mutation found at position 1329, being A changed
to G, is coincident with the 39 splice site of intron 5. To evaluate
the putative use of cryptic splicing sites by the novel mutation, we
used the human splicing finder (HSF) V.2.4.1.tool [20]. An
inactive site with a difference in the consensus value (DCV) of 2
32,5% associated to c.652-2A.G mutation and two strong cryptic
splice sites with a CV higher than 80% (one in the middle of intron
5 and one in exon 6) were predicted (Figure 1C).
Functional Assays
Enzyme activity and Western Blot analysis. To assess the
influence of the different base substitutions in the coding region of
21-hydroxylase, the activity of the normal protein with those of the
various mutant forms were compared. All mutant forms of
CYP21A2 were transiently expressed in COS-7 cells [21], and
enzyme activities in intact cells assayed by using the two natural
substrates for 21-hydroxylase, progesterone, and 17-OHP.
Figure 2 shows the percentage of the remaining activity of all
aminoacidic mutants of CYP21A2 in comparison with the activity
of the WT that was arbitrarily defined as 100%. As shown, for
both substrates, the enzymatic residual activity for all the isolated
mutations was lower than 50%.
Considering that the mutations p.E431K and p.D322G were
found in the same allele in one NCCAH patient, the combined
effect of the two missense mutations was also analyzed. Both
mutations were synergistic, resulting in a reduction of the activity
near to a 2% and 5% of the WT activity for 17-OHP and
progesterone, respectively. Table 1 summarizes the results of the
in vitro enzymatic activity found for the alleles with the novel
mutations found in these patients. Isolated p.E431K and p.D322G
mutations have residual enzymatic activities of 26.263.8% and
41.668.4%, respectively, when 17-OHP was assayed as a
substrate, and 24.267.4% and 32.4616.7%, respectively, for
progesterone. As a control, p.I172N mutation associated with the
classical form of the disease was used. In our conditions, p.I172N
residual activity was 1.2260.13%. The presence of NADPH in the
culture media had no effect on enzyme activity (data not shown).
To investigate whether the mutations in CYP21A2 affect the
level of the protein expression, western blot studies were
performed with proteins obtained from homogenates of cells
transfected with the different constructs. Figure 3 shows a
representative western blot analysis. Of note, p.E431K,
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p.D322G and p.E431K+ p.D322G mutations clearly showed a
lower amount of CYP21A2.
Minigene and mRNA analysis. After the bioinformatics
results, we analyze the splicing outcome of the gene bearing the
novel c.652-2A.G mutation. Splicing reporter minigenes were
Figure 1. Representative electropherogram and restriction enzyme assay of the novel splice mutation found. A: Mutation g.1329A.G
(c.652-2A.G) changes an acceptor splice site in intron 5. The change A.G is depicted by an arrow. B: BtgI restriction enzyme assay for c.652-2A.G.
C: control individuals, P: patient. -RE: control without restriction enzyme. MWM: molecular weight marker. C: Cartoon representation of the
bioinformatic results. A fragment of 206 pb ranging from nt 1221 in the 39 end of exon 5 to nt 1425 in the exon 6 was analyzed using the Human
Splicing Finder tool. Only the main sites were included in the diagram. Green square: consensus acceptor site in the intron 5 disrupted by the
mutation; grey squares: putative critic acceptor sites located 59and 39 of the canonical one; grey circles: consensus donor sites.
doi:10.1371/journal.pone.0092181.g001
Figure 2. Residual activity of the different mutants. Enzyme activities were expressed as percentage of wild type CYP21A2 activity that was
defined as 100%. Conversion values are shown for the two natural substrates (17-OHP to 11-deoxycortisol and progesterone to 11-
deoxycorticosterone). Each bar represents the mean 6 S.E.M. of two different colonies for each mutant assayed 2 to 4 times in independent
experiments.
doi:10.1371/journal.pone.0092181.g002
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constructed comprising the genomic region from exon 4 to exon 7
of the CYP21A2 gene, wild type or mutated, inserted in exon 3 of
the a-globin gene (Figure 4C). The vector carrying this construct,
under the control of the a-globin promoter, was transiently
transfected into two different human cells lines, HEK-293 and
HeLa, and in the murine steroidogenic Y-1 cells. After RNA
extraction, splicing was assessed by RT-PCR using primers that
map the junction between the a-globin and the CYP21A2 regions of
the minigene, thus amplifying only the mRNA product of the
transfected minigenes. As a result, we observed that both the
mutated and the WT constructs lead to only one mRNA isoform
each but of different lengths, being the mutant shorter that the
WT (Figure 4A). Sequencing of this PCR products revealed that
the allele with the c.652-2A.G mutation completely abolishes the
use of the canonical splice site. Instead, the use of the cryptic splice
acceptor site within exon 6 created an mRNA with a 16 nt
deletion (Figure 4B). As a consequence, the appearance of a
premature stop codon is predicted 12 nt downstream (Figure 4C).
Table 1. In vitro residual enzymatic activity of the allele bearing the novel mutation found for the patients.
Patient Phenotype Genotype Mean residual activity of the allele with the novel mutation (SEM)
17-OHP Progesterone
1 NCCAH? p.R132C/N 35.4 (7.4) 15.5 (2.7)
2 NCCAH p.R149C/p.V281L 35.8 (14.6) 47.3 (12.9)
3 NCCAH p.M283V/c.283-13A/C.G 16.2 (9.3) 19.0 (6.8)
4 NCCAH p.D322G-p.E431K/p.V281L 2.1 (1.1) 5.6 (3.3)
NCCAH: non.classical CAH. 17-OHP: 17-OH progesterone. Novel mutations are in bold and underlined. Residual activity is expressed as percentage relative to the WT
allele that was considered as 100%.
doi:10.1371/journal.pone.0092181.t001
Figure 3. Expression analysis of the different mutants. A: Representative western blot showing expression levels of wild type CYP21 and the
different mutagenized constructions assayed. B: Densitometric quantification of CYP21A2 expression. Protein levels of the different CYP21A2
constructs were expressed as the ratio between CYP21A2 and b-actin, considering b-galactosidase activity as the control for transfection efficiency.
Bars represent the mean 6 S.E.M of 2 different extracts assayed 2 times each.
doi:10.1371/journal.pone.0092181.g003
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Figure 4. pre-mRNA splicing analysis of wild type (WT) and mutant (MUT) c.652-2A.G CYP21A2 genes. A: Representative polyacrilamide
gel electrophoresis of a Reverse Transcription (RT)- PCR analysis of CYP21A2 minigene mRNAs in 3 cells types: HEK-293, HeLa and Y-1. –T: not
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Discussion
The adrenocortical 21-hydroxylase is one of the key enzymes in
glucocorticoid and mineralocorticoid biosynthesis. Mutations in
the CYP21A2 gene are responsible of CAH due to 21-hydroxylase
deficiency. To date, a great number of different mutations in
CYP21A2 have been described. The majority of these mutations
result in amino acid substitutions that may disturb essential
functional and/or structural motifs of the protein.
In this work, the functional consequence of four previously
reported point CYP21A2 mutations - p.R132C, p.R149C,
p.M283V, p.E431K- found in Argentine patients is analyzed
[12]. We additionally report a novel point mutation in an acceptor
splice site in the intron 5 of the gene found in a CCAH patient. Its
pathogenic functional implications was assessed by bioinformatic
predictions and analyzing the splicing outcome of the gene bearing
the c.652-2A.G mutation.
The putative pathogenic mechanisms of the newly described
mutations coding for aminoacidic substitution of CYP21A2 were
previously analyzed in silico by means of mutagenesis modeling and
protein stability calculations [12]. In the present work, all the
mutant forms showed a lower activity than the WT. In general, the
remaining activity of the isolated mutants was reduced to a lesser
than 50% of the WT activity with both 17-OHP and progesterone.
Accordingly, all the variants predict alleles compatible to the mild
non-classical form of the disease. However, in one NCCAH
patient one novel point mutation -p.E431K- was found in cis with
the p.D322G mutation. The highest decrease in enzyme activity
was obtained when both mutations were assayed in the same
construction, with a residual activity most likely related to the SV
form of the disease. Furthermore, the variant p.D322G in isolation
revealed a decrease in enzyme activity similar to that described by
Bleicken et al. [22].
To determine whether the mutations in CYP21A2 affect protein
levels or its activity only, western blot studies were performed with
proteins obtained from homogenates of cells transfected with the
different constructs. Western blot analysis revealed that the
amount of p.R132C, p.R149C and p.M283V mutant proteins is
comparable to that of the wild type, suggesting that the reduction
in enzymatic activity is not due to a significant decrease in the
amount CYP21A2 but rather in the activity itself. For instance,
R132 is part of a cluster of basic amino acids suggested to be
involved in the redox partner interaction with P450 Oxido
Reductase (POR) [11]. Mutations in these basic amino acids are
likely to cause electrostatic disturbances so an impairment of the
enzyme activity by C132 mutation could be expected. These
suggestions are supported by the in silico modeling results recently
published by Haider et al. [13] using as template the crystallized
bovine CYP21 that shares 79% sequence identity with human
CYP21A2. On the other hand, in a previous paper [12] we
predicted that the change of a methionine by a cystein in residue
149 could destabilize the protein. Likewise, Haider et al. [13]
suggested that the presence of p.R149C mutation could disrupt a
salt-bridge interaction with E162 and hence a localized destabi-
lization of the tertiary structure of the protein is predicted.
Moreover, a recent work illustrated that a p.R149P mutation
found in the CYP21A2 gene showed a residual activity of 16.9%
and 23.4% for the conversion of progesterone and 17-OHP,
respectively [28]. In addition, the reduction in the enzymatic
activity of the mutant p.M283V is in accordance with the
positioning of the methionine 283 in the well-conserved helix I,
which was suggested to be involved in both heme binding and
substrate recognition [11].
The determination of protein levels by western blot in cells
transfected with p.E431K, p.D322G and p.E431K plus p.D322G
mutations indicate that there is a clear decrease in the amount of
protein, suggesting in these mutants either an impaired synthesis
or an enhanced degradation of the CYP21A2 protein. A decrease
in protein stability and hence in the half-life has been described for
p.R483P mutant [29] and a reduction in the amount of protein in
the presence of p.D322G mutation was also demonstrated by
Bleicken et al. [22]. Therefore, the reduction in the enzyme activity
in cells transfected with p.E431K and p.D322G could be
explained by a decrease in protein expression. Conversely, the
synergistic effect determined in enzyme activity when both
mutations are located in cis is not related to a similar extent
reduction in the amount of the protein, suggesting an additional
effect in substrate conversion. On the other hand, the results of
western blot analysis for p.E431K are in contrast with the
prediction that this mutation marginally stabilizes the protein [12].
Since the mutation introduces a lysine, we wonder if a new
ubiquitination site was generated. The search for such a consensus
motif revealed no obvious ubiquitination site (data not shown).
It is well documented that most of the 21-hydroxilase deficient
patients are compound heterozygotes carrying different CYP21A2
mutations in each allele, being the phenotype of the affected
individual dependent on the milder gene defect [10]. Accordingly,
based on the almost null residual activity of the protein codified by
the c.283-13A/C.G on the homologous allele in one of the
NCCAH patients, we previously predicted the p.M283V as a mild
mutation [12]. In the present paper, in vitro data further confirmed
this prediction. Moreover, we recently genotyped a second patient
of our cohort showing a NCCAH phenotype as p.M283V/
macroconversion (data not shown). However, in the other patients
described by Minutolo et al. [12] (Table 1), the presence of another
mild mutation or the lack of demonstrable mutation on the second
allele precluded the prediction of the enzymatic activity of the
novel allele. Although the use of approximate models has allowed
making some predictions regarding activity with certain accuracy
[11–13], the magnitude of the putative impairment was not always
reliable predicted. Consequently, in vitro analyses seem to be
necessary to further clarify the severity of a mutated allele for an
accurate genetic counseling. Moreover, a second point mutation
on the same allele have been described in 21-hydroxylase
deficiency and none of the in silico models predicted their
biological consequences. Indeed, the functional studies performed
in this work and in other ones [30–33] revealed low enzymatic
activities for those alleles with two mild mutations in cis.
The presence of a single CYP21A2 mutated allele has been
previously described in patients diagnosed with 21-hydroxylase
deficiency [28,34–40]. In fact, in patient 1 and after sequencing
the entire gene, the minimal promoter and the regulatory regions,
no mutations with the exception of p.R132C were found [12].
Several studies have shown that heterozygous carriers of CYP21A2
mutations may have an increased risk of hyperandrogenic
transfected. -RT: without reverse transcription: bands observed in both lanes correspond to PCR products from plasmid DNA used as template. MWM:
Molecular weight marker. B: Representative electropherograms of the RT-PCR products. Junction of exon 5 and 6 are depicted in each case.
Underlined, the 16 nt present in the wild type sequence and absent in the mutant one. C: Diagram summarizing the strategy used and the results
obtained. Letters above the sequence represent the codified aminoacids. The 16 nt deletion is in italic and underlined. Dashed arrows represent
primers used in the RT-PCR spanning the a-globin and CYP21A2 regions of the minigene.
doi:10.1371/journal.pone.0092181.g004
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symptoms and could exhibit ACTH-stimulated 17-OHP values
similar to those described in patients with the non-classical form of
the disease [41,42]. Nevertheless, basal and stimulated 17-OHP
values in this patient (5.7 and 30 ng/mL, respectively [12]),
markedly exceeded the currently cut-off levels used for the
diagnosis of NCCAH due to 21-hydroxylase deficiency [16,43].
Besides, and even though an overall good genotype-phenotype
correlation have been reported for this disorder, a recent work by
New et al [44] described that almost half of the genotypes showed a
discordant phenotype. These observations as a whole might
indicate that other genetic and/or environmental factors could
contribute to modulate the activity of the CYP21A2 enzyme in vivo
and/or the possible clinical manifestation exhibited by the
patients.
In addition, in the present work, we describe a novel acceptor
splice mutation in intron 5 in compound heterozygosity with the
rare p.R483Q mutation found in a SV patient. In silico analysis
predicted the disruption of the canonical splicing site by the c.652-
2A.G mutation. Besides, two strong putative cryptic splicing sites,
one located in the intron 5 and one in exon 6 were predicted. By
functional analyses using transient expression of splicing reporter
minigenes transfected into HEK-293, HeLa and Y-1 cells, we
demonstrate that the allele with the c.652-2A.G mutation
completely abolishes the use of the canonical splice site. Instead,
in the three cell lines analyzed, the use of the cryptic splicing
acceptor site within exon 6 created an mRNA with a 16 nt
deletion leading to the appearance of a premature stop codon.
In vivo, two possible and non exclusive mechanisms could be
related to the pathogenic consequence of c.652-2A.G mutation:
the putative formation of a truncated, unstable protein with no
enzymatic activity and the mRNA degradation due to a nonsense
mediated decay (NMD) mechanism. The in vitro approach used in
this paper relies on in vitro mRNA over-expression from a strong
promoter and thus unable to address whether NMD occurs in vivo
and its relevance on the observed pathogenic phenotype.
Nevertheless, and regardless of the underlying mechanism, a
severe allele is strongly suggested by the substitution in the intron 5
acceptor splice site.
It should be noted that although mutations in the consensus
splicing acceptor or donor sites of the CYP21A2 gene have been
previously reported in 21-hydroxylase deficient patients [19,45–
48], functional consequences have only been addressed for the
c.282+1G.A (IVS2+1G.A) mutation [49]. Furthermore, the
strategy used in this paper allowed for the first time, the
demonstration of the consequence of a splice mutation also in a
steroidogenic cell line. Similarly to our finding, the c.282+1G.A
mutation revealed the use of a cryptic splicing site in the CYP21A2
gene. Differently to the mutation described here, two types of
transcripts from this mutant CYP21A2 gene were reported.
Although the mutation in the intron 5 acceptor splicing site
predicts a severe allele, the patient herein described disclosed a
phenotype most likely related to the previously reported in vitro
enzymatic activity of the rare p.R483Q allele [50,51]. To our
knowledge, only three other patients with the p.R483Q mutation
were reported: one boy diagnosed as NCCAH [52] and two girls
with clinical symptoms and hormonal values compatible with the
classical SV form [50,51]. Considering that the distinction
between SV and NCCAH is more difficult in males, the patient
herein described supports the evidence that the p.R483Q
mutation might be related to the SV form of the disease rather
than to the non-classical one.
In conclusion, we described the functional consequences of four
previously described mutations and a novel one found in 21-
hydroxylase-deficient patients from the Argentinean population.
All the isolated mutants coding for aminoacidic substitution of
CYP21A2 predict mild alleles related to the NCCAH form, while
the presence of two mild mutations on the same allele predicts a
classical SV one. The c.652-2A.G mutation is herein described
for the first time. We found that the allele with this acceptor splice
site mutation completely abolishes the use of the canonical splice
site. Although bioinformatic tools predicted the putative use of two
different cryptic splicing sites, functional analyses revealed the use
of only the cryptic splice acceptor site within exon 6. A severe
allele is strongly suggested due to the appearance of a premature
stop codon.
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